Source: ERS Course 2015



Rating:

Share or cite this content

Citations should be made in the following way:
O. Eickelberg (Munich, Germany). From target to preclinical evidence : the “Lung fibrosis” experience. ERS Course 2015

Member's Comments

No comment yet.

Related content which might interest you: Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 From target to preclinical evidence: the “Pneumonia and ARDS” experience Source: ERS Course 2015 Year: 2015 Does the lung clearance index track with disease progression in early childhood? Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Computed-tomography-based radiomics features for staging of interstitial lung disease – transferability from experimental to human lung fibrosis - a proof-of-concept study Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab? Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab? Year: 2013 A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer Source: Eur Respir J 2013; 41: 262-269 Year: 2013 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence Source: Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018 Year: 2018 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Ability of lung clearance index to track changes in a routine clinical CF setting Source: International Congress 2015 – Paediatric respiratory physiology Year: 2015 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019